Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard Risk B-precursor ALL Treatment Optimization
NCT00103285Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Apr 2005
- Primary completion
- Dec 2013
- Modality
- Therapeutic Enzymes
- Countries
- 5
01
Overview
A Phase 3 trial of pegaspargase in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Children's Oncology Group. Started Apr 2005; status: completed.
02
Drugs
pegaspargase
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT00103285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00103285.